A competitor announces a collaboration. The immediate questions are practical: Which assets are involved? How far have they progressed? Which territories and rights does the agreement cover? A useful competitive intelligence setup should help your team answer those questions with records it can inspect.
The same intelligence can reach a team in different ways. Analysts may work directly in a dedicated application. Product and data teams may bring structured records into an internal system. Researchers may want an AI assistant to call specialist tools as part of a conversation.
Those needs point to three access models: App, API and MCP. Choosing among them is less about which option is more advanced and more about where the work happens, who maintains the workflow and how the result will be reviewed.
Three ways to use pharma competitive intelligence
| Access model | Best fit | What your team manages | Typical output |
|---|---|---|---|
| App | Analysts need to search, explore and review intelligence directly | A ready-to-use research application | Searches, profiles, landscapes and reviewed exports |
| API | Product or data teams are building a repeatable internal system | Code, data models and application logic | Structured records inside dashboards, alerts or data pipelines |
| MCP | Researchers want an AI assistant to call specialist tools during a task | Prompts, tool calls and evidence review | A sourced answer, comparison or research brief inside the AI workflow |
An application offers the shortest route from a question to analyst review. An API gives a development team control over how intelligence enters an internal product or process. MCP allows a compatible AI client to invoke specialist operations during a research conversation. These paths can also work together.
1. App: work directly in Patsnap Eureka
Patsnap Eureka Life Sciences gives researchers a ready-to-use application with AI agents for questions involving drugs, targets, diseases, clinical results, patents, papers and company strategy.
- Best for: Researchers and analysts who want to investigate a question without first building an internal interface.
- Common use cases: Competitor research, target and asset assessment, clinical benchmarking, lead research and source-linked life-sciences questions.
- Your team manages: The research question, supporting context, follow-up direction, evidence review and final interpretation.
- Ask during evaluation: Does the relevant Eureka agent produce the output your team needs, and can reviewers trace material findings to dated records and sources?
An app is often the most natural starting point for exploratory work. An analyst can follow a new lead, refine the scope and inspect individual records without waiting for an engineering change.
The application does not remove the need for a sound research method. A large result set is not a competitive conclusion; a company may have several relationships to the same asset; and a global development stage does not describe every indication. Test the application with a case your team already understands and check how clearly it preserves those distinctions.
2. API: build intelligence into your own system
Patsnap Open Platform APIs provide structured access for backend services, internal research products and data workflows. Life-sciences endpoints cover drug, deal and clinical information.
- Best for: Organizations that need intelligence inside a dashboard, monitoring process, internal search product or another maintained application.
- Common use cases: Retrieve drug records, enrich an asset list, link transactions to assets, monitor defined events and present selected fields in a team-specific interface.
- Your team manages: Requests, identifiers, storage, refresh logic, permissions, interface behavior and quality checks.
- Ask during evaluation: Do the endpoints cover the required records and fields, and can your system handle pagination, updates and missing values correctly?
For example, the Drug basic information API returns structured fields such as targets, diseases and active organizations. The Drug deal information API provides transaction details for an identified deal. Drug monitoring endpoints can support specified event types, including changes involving development stages, clinical trials, deals, patents, papers and news.
APIs provide the building blocks rather than a finished competitive intelligence workflow. Your team decides which endpoints to combine, how to reconcile entities, when to refresh records and which findings require human review. This path makes sense when that control justifies ongoing product and engineering ownership.
3. MCP: bring specialist tools into an AI workflow
Patsnap Open MCP servers make specialist operations available to a compatible AI client. During a conversation, the assistant can call those operations, organize the returned records and help the researcher decide what to examine next.
- Best for: Researchers who already work in an AI assistant and want specialist retrieval inside that environment.
- Common use cases: Answer a bounded question, compare selected assets, inspect a competitor pipeline, retrieve related transactions and prepare a sourced research brief.
- Your team manages: The question, scope, connected servers, review standard and any decision based on the result.
- Ask during evaluation: Does the client discover the right operations, call them with the intended scope and preserve source references and unresolved gaps in its answer?
For questions that span several life-sciences record types, Pharma Intelligence provides access to drug, trial and deal retrieval. Drug & Asset focuses on drug records and development milestones. Clinical Trials fits questions that depend on registered studies or trial results.
Their capabilities can overlap. Start with the operations the question requires and check what is already available in the connected environment. Adding another server is useful only when it supplies a missing operation or creates a clearer boundary for the work.
Choose the access model around who owns the workflow
Start with the app when an analyst owns the investigation. Start with APIs when a product or data team owns a maintained system. Start with MCP when the work happens in an AI assistant and the immediate deliverable is a researched answer.
| Team requirement | Start with | Why |
|---|---|---|
| Explore an unfamiliar landscape interactively | App | The analyst can change direction and inspect records directly |
| Standardize a recurring internal dashboard | API | The team controls data flow, interface and refresh behavior |
| Research a bounded question in Claude, Codex or another compatible client | MCP | The assistant can call the relevant specialist operation during the task |
| Maintain a governed workflow with analyst review | App + API | Analysts investigate while the system distributes selected outputs |
| Draft AI-assisted briefs from structured evidence | MCP | The researcher stays in a conversational workflow while reviewing retrieved records |
The output format alone will not settle the choice. A report can come from an app, an internal system or an AI workflow. The more useful distinction is who owns the process: the analyst, the development team or the researcher working with an AI assistant.
See the MCP path in practice
A useful MCP evaluation starts with a case whose important facts can be checked independently. For this article, Pharma Intelligence was asked to retrieve the drug record for patritumab deruxtecan and search for related deals in a separate call.
Retrieve the drug record for patritumab deruxtecan and search related deals separately. Show company roles, global highest development stage, deal dates, assets and included or excluded territories. Preserve record references and source links. Flag shortened lists and conflicting company roles. Check the original announcement before summarizing rights or financial terms; do not infer that a collaboration ended from an inactive company field.Copy and adapt to your project.
On September 21, 2026, the drug search returned one matched asset. The separate deal search returned three matched records, all three retrieved. This is an asset-specific test of the MCP output, not a test of the Eureka application, the equivalent REST endpoints or the coverage of the entire market.
Global highest stage: Phase 3. The response displayed three research-disease entries while reporting 48, and three active-organization entries while reporting seven. The displayed lists are summaries.
The record includes three ADCs and identifies global territory with Japan excluded. Read the announcement before turning these fields into a rights statement.
A separate record concerns a combination-study collaboration. Its presence does not establish the same commercialization rights as the 2023 transaction.
The drug record includes Merck-related entities in different role lists. Merck's current pipeline still describes development with Daiichi Sankyo. An inactive entity entry alone cannot establish that the collaboration ended.
The third result was a 2020 research collaboration involving Gustave Roussy. Keeping the records separate prevents the assistant from presenting every research partner as a commercial license holder.
Check financial terms against the announcement
The 2023 deal result contained numeric payment fields, but the selected response did not label their currency or units. The original company announcement provides the necessary context: $4 billion upfront, $1.5 billion in continuation payments and up to $16.5 billion tied to future sales milestones, across three ADCs.
The potential $22 billion total is neither cash already paid nor a valuation assigned solely to patritumab deruxtecan. The MCP made the transaction record available; the reviewer still had to preserve the scope and conditions of the source.
Keep asset status and indication events separate
The drug summary reported a global highest stage of Phase 3. Separately, a May 2025 company release described withdrawal of a specific US accelerated-approval application. Neither statement means that every indication is in Phase 3 or that the entire program ended.
The same interpretation rule applies across access models: keep the unit of analysis visible. An app, API or MCP may surface the record differently, but the reviewer must still distinguish an asset-level field from an indication-specific event.
Test each option against the same research brief
Use the same known asset set and decision question when evaluating an app, API or MCP path. That keeps the comparison tied to the work instead of the length of each feature list.
| Evaluation question | Evidence to collect |
|---|---|
| Does it identify the right assets? | Known aliases, missing candidates and duplicate handling |
| Can it preserve company roles? | Originator, active developer, rights holder and deal counterparty fields |
| Can a reviewer trace the finding? | Record identifiers, source links and source dates |
| Can it represent change? | Milestones, event dates, update behavior and saved baselines |
| Does it fit the operating model? | Analyst usability, engineering ownership or AI-client compatibility |
| Can the team govern the output? | Permissions, review steps, retained queries and approved distribution |
Record separate findings for data fit, workflow fit and access fit. A useful dataset may still be the wrong implementation choice for a team without development capacity. Likewise, a convenient AI connection may not suit a production system that requires controlled requests, predictable processing and maintained governance.
Choose your Patsnap Open integration path
Explore APIs and MCP servers, then test the route that fits your system or AI workflow with one bounded research question.
Frequently asked questions
Is an MCP server a replacement for a pharma intelligence application?
It serves a different working pattern. An application supports direct exploration and record review. MCP lets an AI client invoke exposed operations during a conversation. The best choice depends on the task, the user and the required controls.
When should a team choose an API instead of MCP?
Choose APIs when your software must control requests, data flow, storage, refresh behavior and user experience. Choose MCP when a compatible AI client should decide when to call tools while answering a research question. Some teams use APIs behind maintained systems and MCP for analyst-facing exploration.
Do I need all the life-sciences MCP servers?
No. Connect the operations required by the task. Pharma Intelligence covered the drug and deal searches in this example. Add a focused server when it supplies a needed operation or creates a clearer working boundary.
Can public sources still be part of the workflow?
Yes. Trial registries and dated company disclosures are useful verification sources. They are evidence sources, not alternative access models. The workflow should keep links and dates beside material claims.
Sources and disclosure
Patsnap publishes this guide and provides the application, APIs and MCP services described above. Product capabilities were checked against the linked official pages on September 22, 2026. The access-model guidance is an editorial assessment; no comparative performance, completeness, price or productivity benchmark was conducted.
The worked example comprises one Pharma Intelligence drug search and one deal search, each requested with a three-record page limit. It demonstrates the MCP path only. Returned lists may be shortened; record-level counts and displayed entries are distinguished above. Transaction interpretation uses the linked Merck announcement and pipeline page. No clinical efficacy conclusion, current licensing availability or measured time saving is claimed.